FDA Tried to Stop NMN But THIS Just Happened

JT Jared Taylor

44 views • 10 months ago Save 1 min 4 min read

Video Summary

The FDA has reversed its stance, confirming that beta-nicotenomide mononucleotide (NMN) is lawful for use in dietary supplements. This decision follows nearly three years of pressure from an industry association, which challenged the FDA's initial attempt to block NMN from the market by claiming it was first investigated as a new drug. The association presented evidence that NMN was marketed as a dietary supplement in the United States as early as 2017, thereby not being excluded from the definition of a dietary supplement under the relevant act.

The FDA's acknowledgment of NMN's lawful status in supplements is a significant victory, not only for the supplement itself but also for consumer choice and the ability to decide on personal health choices. This ruling aims to prevent opportunistic companies from monopolizing naturally occurring molecules. With NMN now legally available, increased supply is expected to drive down costs, making it more accessible to a wider population interested in improving their health through natural supplements.

Short Highlights

The FDA has confirmed that NMN is lawful for use in dietary supplements, reversing a previous attempt to exclude it from the market.
This decision stemmed from nearly three years of pressure and legal action from the Natural Products Association (NPA).
The NPA argued that NMN was marketed as a dietary supplement as early as 2017, thus not falling under the "drug preclusion" clause.
The FDA's reversal is seen as a win for consumer choice and the accessibility of natural health molecules.
Increased supply due to the legal status is expected to lower costs, making NMN more affordable for consumers.

Key Details

FDA Reverses Course on NMN Legality [00:00]

After nearly three years, the FDA has confirmed that beta-nicotenomide mononucleotide (NMN) is lawful for use in dietary supplements.
The FDA had previously attempted to block NMN from the supplement market, asserting it was first investigated as a new drug.
The Natural Products Association (NPA) challenged this, filing a citizen petition, a federal lawsuit, and mobilizing support.

The FDA's decision acknowledges that NMN was marketed as a dietary supplement as early as 2017, a key factor in its reclassification and removal from exclusion as a dietary supplement.

FDA has reversed course and confirmed that beta-nicotenomide mononucleotide, NMN, is lawful for use in dietary supplements.

NPA's Challenge and FDA's Acknowledgement [01:00]

The NPA refused to accept the FDA's interpretation and took significant action to challenge it.
These actions included filing a citizen petition, launching a federal lawsuit, and rallying industry and consumer support.
In response to these efforts, the FDA acknowledged evidence of NMN's prior marketing as a supplement.
The agency elaborated on its interpretation of the "drug preclusion" or "race to market" clause within the Dietary Supplement Health and Education Act of 1994.

The association's persistence led the FDA to reconsider its position, confirming that NMN's lawful marketing as a dietary supplement is crucial for determining its market eligibility.

FDA acknowledged evidence that NMN was marketed as a dietary supplement in the United States as early as 2017 and consequently is not excluded from the definition of a dietary supplement.

Broader Implications for Consumers and the Market [03:29]

This victory for NMN is framed as a win for individuals making their own health decisions, particularly concerning safe, naturally occurring molecules.
The ruling helps prevent companies from monopolizing naturally occurring molecules and potentially pricing them out of reach for consumers.
With NMN now legal, companies can sell it freely, and e-commerce platforms can offer it more widely.
This increased availability is expected to lead to greater supply, driving down costs and making NMN more affordable for those with financial constraints.

The resolution of the NMN saga is anticipated to foster a more competitive market, benefiting consumers seeking to improve their health through accessible natural supplements.

This is a huge win for NMN. not just for NMN, but for you and for me and for preserving our our opportunities to make our own decisions about what we want to do with our own health and what we want to decide to put into our bodies for that matter, especially when it comes to healthy, naturally occurring molecules that are shown to be safe.